Drug intelligence / Profile preview

hMAb173

Development stage: Preclinical
Lead developer: Vasgene Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

hMAb173 is a humanized monoclonal antibody that targets the Axl receptor tyrosine kinase. Developed by VasGene Therapeutics, it has been investigated primarily for the treatment of renal cell carcinoma (RCC). The antibody exerts its anti-tumor effects by binding to Axl, leading to a reduction in Axl protein levels and subsequent inhibition of the PI3K signaling pathway. This results in decreased tumor cell proliferation and the induction of apoptosis. In preclinical models, hMAb173 has demonstrated significant efficacy, including a 78% inhibition of RCC tumor growth in vivo.

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on hMAb173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hMAb173.

Explore the full profile